Back to Journals » Clinical Ophthalmology » Volume 4

Antiviral selection in the management of acute retinal necrosis

Authors Tam PM, Hooper CY, Lightman S

Published 22 December 2009 Volume 2010:4 Pages 11—20

DOI https://doi.org/10.2147/OPTH.S6390

Review by Single-blind

Peer reviewer comments 3


Patrick MK Tam1, Claire Y Hooper2, Susan Lightman2

1Department of Ophthalmology and Visual Sciences, The Chinese University of Hong Kong, Prince of Wales Hospital, N.T., Hong Kong, People’s Republic of China; 2Institute of Ophthalmology, Moorfields Eye Hospital, London, UK

Abstract: There is no consensus on the optimal antiviral regimen in the management of acute retinal necrosis, a disease caused by herpetic viruses with devastating consequences for the eye. The current gold standard is based on retrospective case series. Because the incidence of disease is low, few well-designed, randomized trials have evaluated treatment dosage and duration. Newer oral antiviral agents are emerging as alternatives to high-dose intravenous acyclovir, avoiding the need for inpatient intravenous treatment. Drug resistance is uncommon but may also be difficult to identify. Antiviral drugs have few side effects, but special attention needs to be paid to patients who have underlying renal disease, are pregnant or are immunocompromised.

Keywords: acute retinal necrosis, acyclovir, herpes, retinitis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]